Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 54

References for PMC Articles for PubMed (Select 21346169)

1.

Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers.

Von Hoff DD, Stephenson JJ Jr, Rosen P, Loesch DM, Borad MJ, Anthony S, Jameson G, Brown S, Cantafio N, Richards DA, Fitch TR, Wasserman E, Fernandez C, Green S, Sutherland W, Bittner M, Alarcon A, Mallery D, Penny R.

J Clin Oncol. 2010 Nov 20;28(33):4877-83. doi: 10.1200/JCO.2009.26.5983. Epub 2010 Oct 4.

2.

Recommendations for biomarker identification and qualification in clinical proteomics.

Mischak H, Allmaier G, Apweiler R, Attwood T, Baumann M, Benigni A, Bennett SE, Bischoff R, Bongcam-Rudloff E, Capasso G, Coon JJ, D'Haese P, Dominiczak AF, Dakna M, Dihazi H, Ehrich JH, Fernandez-Llama P, Fliser D, Frokiaer J, Garin J, Girolami M, Hancock WS, Haubitz M, Hochstrasser D, Holman RR, Ioannidis JP, Jankowski J, Julian BA, Klein JB, Kolch W, Luider T, Massy Z, Mattes WB, Molina F, Monsarrat B, Novak J, Peter K, Rossing P, Sánchez-Carbayo M, Schanstra JP, Semmes OJ, Spasovski G, Theodorescu D, Thongboonkerd V, Vanholder R, Veenstra TD, Weissinger E, Yamamoto T, Vlahou A.

Sci Transl Med. 2010 Aug 25;2(46):46ps42. doi: 10.1126/scitranslmed.3001249.

PMID:
20739680
3.

The grand challenge to decipher the cancer proteome.

Hanash S, Taguchi A.

Nat Rev Cancer. 2010 Sep;10(9):652-60. doi: 10.1038/nrc2918.

PMID:
20733593
4.

Antibody-based proteomics: fast-tracking molecular diagnostics in oncology.

Brennan DJ, O'Connor DP, Rexhepaj E, Ponten F, Gallagher WM.

Nat Rev Cancer. 2010 Sep;10(9):605-17. doi: 10.1038/nrc2902. Epub 2010 Aug 19. Review.

PMID:
20720569
5.

Bioorthogonal chemistry amplifies nanoparticle binding and enhances the sensitivity of cell detection.

Haun JB, Devaraj NK, Hilderbrand SA, Lee H, Weissleder R.

Nat Nanotechnol. 2010 Sep;5(9):660-5. doi: 10.1038/nnano.2010.148. Epub 2010 Aug 1.

6.

A microfluidic platform for systems pathology: multiparameter single-cell signaling measurements of clinical brain tumor specimens.

Sun J, Masterman-Smith MD, Graham NA, Jiao J, Mottahedeh J, Laks DR, Ohashi M, DeJesus J, Kamei K, Lee KB, Wang H, Yu ZT, Lu YT, Hou S, Li K, Liu M, Zhang N, Wang S, Angenieux B, Panosyan E, Samuels ER, Park J, Williams D, Konkankit V, Nathanson D, van Dam RM, Phelps ME, Wu H, Liau LM, Mischel PS, Lazareff JA, Kornblum HI, Yong WH, Graeber TG, Tseng HR.

Cancer Res. 2010 Aug 1;70(15):6128-38. doi: 10.1158/0008-5472.CAN-10-0076. Epub 2010 Jul 14.

7.

Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer.

Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L, Inserra EJ, Ulman M, Springer S, Nakamura Z, Moore AL, Tsukrov DI, Kempner ME, Dahl DM, Wu CL, Iafrate AJ, Smith MR, Tompkins RG, Sequist LV, Toner M, Haber DA, Maheswaran S.

Sci Transl Med. 2010 Mar 31;2(25):25ra23. doi: 10.1126/scitranslmed.3000403.

8.

Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies.

Lahat G, Zhu QS, Huang KL, Wang S, Bolshakov S, Liu J, Torres K, Langley RR, Lazar AJ, Hung MC, Lev D.

PLoS One. 2010 Apr 16;5(4):e10105. doi: 10.1371/journal.pone.0010105.

9.

Assessment of automated image analysis of breast cancer tissue microarrays for epidemiologic studies.

Bolton KL, Garcia-Closas M, Pfeiffer RM, Duggan MA, Howat WJ, Hewitt SM, Yang XR, Cornelison R, Anzick SL, Meltzer P, Davis S, Lenz P, Figueroa JD, Pharoah PD, Sherman ME.

Cancer Epidemiol Biomarkers Prev. 2010 Apr;19(4):992-9. doi: 10.1158/1055-9965.EPI-09-1023. Epub 2010 Mar 23.

10.

Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed.

D'Alfonso T, Liu YF, Monni S, Rosen PP, Shin SJ.

Am J Surg Pathol. 2010 Apr;34(4):575-81. doi: 10.1097/PAS.0b013e3181d65639.

PMID:
20216378
11.

Medicine. Cancer's circulation problem.

Kaiser J.

Science. 2010 Feb 26;327(5969):1072-4. doi: 10.1126/science.327.5969.1072. No abstract available.

PMID:
20185704
12.

Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner.

Erez N, Truitt M, Olson P, Arron ST, Hanahan D.

Cancer Cell. 2010 Feb 17;17(2):135-47. doi: 10.1016/j.ccr.2009.12.041. Epub 2010 Feb 4. Erratum in: Cancer Cell. 2010 May 18;17(5):523. Arron, Sarah Tuttleton [added].

13.

Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers.

Saadi A, Shannon NB, Lao-Sirieix P, O'Donovan M, Walker E, Clemons NJ, Hardwick JS, Zhang C, Das M, Save V, Novelli M, Balkwill F, Fitzgerald RC.

Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2177-82. doi: 10.1073/pnas.0909797107. Epub 2010 Jan 13.

14.

Systematic review: comparative effectiveness of core-needle and open surgical biopsy to diagnose breast lesions.

Bruening W, Fontanarosa J, Tipton K, Treadwell JR, Launders J, Schoelles K.

Ann Intern Med. 2010 Feb 16;152(4):238-46. doi: 10.7326/0003-4819-152-1-201001050-00190. Epub 2009 Dec 14. Review.

PMID:
20008742
15.

Drivers of biodiagnostic development.

Giljohann DA, Mirkin CA.

Nature. 2009 Nov 26;462(7272):461-4. doi: 10.1038/nature08605. Review.

16.

Nanoparticle-based bio-barcode assay redefines "undetectable" PSA and biochemical recurrence after radical prostatectomy.

Thaxton CS, Elghanian R, Thomas AD, Stoeva SI, Lee JS, Smith ND, Schaeffer AJ, Klocker H, Horninger W, Bartsch G, Mirkin CA.

Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18437-42. doi: 10.1073/pnas.0904719106. Epub 2009 Oct 19.

17.

Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.

Tan DS, Thomas GV, Garrett MD, Banerji U, de Bono JS, Kaye SB, Workman P.

Cancer J. 2009 Sep-Oct;15(5):406-20. doi: 10.1097/PPO.0b013e3181bd0445. Review.

PMID:
19826361
18.

Fast and sensitive pretargeted labeling of cancer cells through a tetrazine/trans-cyclooctene cycloaddition.

Devaraj NK, Upadhyay R, Haun JB, Hilderbrand SA, Weissleder R.

Angew Chem Int Ed Engl. 2009;48(38):7013-6. doi: 10.1002/anie.200903233. No abstract available.

19.

Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features.

Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, Fan C, Zhang X, He X, Pavlick A, Gutierrez MC, Renshaw L, Larionov AA, Faratian D, Hilsenbeck SG, Perou CM, Lewis MT, Rosen JM, Chang JC.

Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13820-5. doi: 10.1073/pnas.0905718106. Epub 2009 Aug 3.

20.

Identification of splenic reservoir monocytes and their deployment to inflammatory sites.

Swirski FK, Nahrendorf M, Etzrodt M, Wildgruber M, Cortez-Retamozo V, Panizzi P, Figueiredo JL, Kohler RH, Chudnovskiy A, Waterman P, Aikawa E, Mempel TR, Libby P, Weissleder R, Pittet MJ.

Science. 2009 Jul 31;325(5940):612-6. doi: 10.1126/science.1175202.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk